abstract |
An anti-CD20 antibody and a method for treating a B cell-related disease are provided. The anti-CD20 antibody is a monoclonal antibody, and the antibody that binds to CD20 is humanized or chimeric. Humanized 2H7 variants include those with amino acid substitutions in FRs and similar mature variants with changes in transplanted CDRs. The anti-CD20 antibody has an effect of depleting primate B cells in vivo, and can treat CD20 positive malignant tumors and autoimmune diseases. [Selection figure] None |